NHS takes makers of generic drugs to court for price fixingBMJ 2004; 329 doi: http://dx.doi.org/10.1136/bmj.329.7456.12-a (Published 01 July 2004) Cite this as: BMJ 2004;329:12
- Owen Dyer
The NHS is seeking over £100m ($183m; €150m) in compensation from two manufacturers of generic drugs that allegedly formed a cartel to fix artificially high prices for ranitidine, the generic form of the ulcer drug Zantac.
The case is the latest to emerge from an ongoing investigation by the NHS Counter Fraud and Security Management Service into anticompetitive behaviour in the generic drug industry. Jim Gee, chief executive of the service, said the overcharging for ranitidine was the most serious example yet uncovered and may have deprived the NHS of up …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial